Session: SUN 758-779-Cardiometabolic Risk & Vascular Biology
Poster Board SUN-770
Study Design: Study included 16,242 women and 9,061 men from the TURDEP-II (2010) survey representing age-specific adult Turkish population.
Results: Median (1-99 percentile) IGF1 levels in the reference population composed of 2,455 healthy men and women were 149 (36.1-384.3) and 143 (30.4-384.3) ng/mL, respectively. IGF1 levels were higher in men than women in all 5-yr age intervals, and decreased with age in both sexes, whereas IGFBP3 levels and IGF1/IGFBP3 ratios were higher in women than men and decreased with age in both sexes (p<0.001, for all). People living in the East part had lower IGF1 than all other regions (p<0.001).
Correlation analysis controlled for region, rural/urban, age, sex, alcohol, tobacco, BMI, waist and blood pressure (BP) revealed that serum IGF1 levels positively correlated with IGFBP3, creatinine, HDL-chol, FT4, insulin, HOMA-IR, vitB12, pholates, cystatin-C and eGFR, and inversely correlated with hsCRP levels. Whereas serum IGFBP3 levels positively correlated with FPG, OGTT-1hPG, HbA1c, HOMA-IR, creatinine, cystatin-C, triglycerides, LDL-chol, nonHDL-chol, FT4, insulin, vitB12, pholates and vit25(OH)D; and inversely correlated with eGFR, hsCRP and PTH levels.
Serum IGF1 levels corrected for region, rural/urban, age, sex, tobacco, alcohol, BMI, waist, BP, creatinine and serum lipids showed decreasing trend from normal glucose tolerance through known diabetes. IGF1 levels were even more reduced if hypertension and/or obesity accompanied to diabetes.
Comparison of lowest and highest quintiles of IGF1 indicated that obesity, hypertension and diabetes were more prevalent in the lowest quintile (obesity: 45.5% vs. 20.8%, central obesity: 63% vs. 34%, known hypertension: 27.9% vs. 7.3%, new hypertension: 17.6% vs. 7.9%, new diabetes: 11.2% vs. 3.5%, total diabetes: 24.8% vs. 7.2%, and pre-diabetes: 32.7% vs. 26.9%).
Conclusion: IGF1 levels decreased with age. Low IGF1 associated with higher risk of obesity, hypertension and diabetes.
Nothing to Disclose: IS, NCO, HB, AT, BO, YT, FA, FA
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters